((Rami Komrokji, MD))
The extended half-life of VYXEOS allows for greater drug exposure within the plasma and bone marrow.
Based on the pharmacokinetic Phase 1 trial data, the median half-lives of daunorubicin and cytarabine are prolonged with VYXEOS versus free drug.
For VYXEOS, the estimated half-life of daunorubicin and cytarabine were 32 hours and 40 hours, respectively, when administered in VYXEOS.
In the VYXEOS Phase 3 trial, bone marrow assessments were performed 14 to 21 days after induction, and a follow-up evaluation was performed 5 to 14 days later if the Day 14 to 21 bone marrow was nonevaluable or assessment of a morphologic leukemia-free state was equivocal.
At our institution, we typically assess bone marrow between Days 14 and 21, and a growth factor is started once blasts are undetectable.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION